Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PANDORA

Financiado

Pandemics Outbreaks Rationalized towards a universal therapy to eliminate intra...

Pandemics Outbreaks Rationalized towards a universal therapy to eliminate intracellular pathogens and drug resistance I propose here a research vision that aims to revolutionise the way we cure infections caused by intracellular pathogens, with the aim to find a universal therapy to infectious diseases that will also counteract the development of... ver más

30/09/2025

UMIL

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

UNIVERSITA DEGLI STUDI DI MILANO No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 4 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-12-05

ERC-2019-STG: ERC Starting Grant

I+D

Cerrada hace 6 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

4 Participantes

UMIL

1.27M€ | Lider

UVE

607.68K€ | Participante

FUNDACIO INSTITUT DE BIOENGI...

165.36K€ | Participante

INGM

62.50K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

EEBB-I-12-04561 DISEÑO Y CARACTERIZACION MOLECULAR Y FUNCIONAL DE VIRUS ARTI... 10K€ Cerrado

CodeSphere CodeSphere Discovering Therapeutic Nanoparticles by Molecu... 150K€ Cerrado

RTI2018-098027-B-C21 NUEVOS NANOVEHICULOS PARA TERANOSTICA DE ENFERMEDADES CEREBR... 151K€ Cerrado

CTQ2013-48767-C3-3-R DESARROLLO DE DISPOSITIVOS NANOESTRUCTURADOS COMO PLATAFORMA... 77K€ Cerrado

CTQ2013-48767-C3-2-R DESARROLLO DE DISPOSITIVOS NANOESTRUCTURADOS COMO PLATAFORMA... 86K€ Cerrado

CTQ2013-48767-C3-1-R DESARROLLO DE DISPOSITIVOS NANOESTRUCTURADOS COMO PLATAFORMA... 150K€ Cerrado

Duración del proyecto: 69 meses Fecha Inicio: 2019-12-05
Fecha Fin: 2025-09-30

Líder del proyecto

UNIVERSITA DEGLI STUDI DI MILANO No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 1M€

Descripción del proyecto I propose here a research vision that aims to revolutionise the way we cure infections caused by intracellular pathogens, with the aim to find a universal therapy to infectious diseases that will also counteract the development of drug resistance. In PANDORA, I will specifically focus on eradicating human tuberculosis, one of the worst pandemics so far. To do this, I will first probe what are the molecular ‘bar-codes’ of infected cells, namely those specific membrane proteins that cells express upon infection. I will use this to reversely engineer a repertoire of super-selective polymeric nanoparticles - known as Polymersomes - that will carry ligands to recognise, bind, and selectively attack infected cells only, while leaving non-infected cells completely untouched. Such nanocarriers will access the infected cells and locally deliver their payload, which is the core technology of the therapy. Such technology will be inspired by what nature invented: I will reproduce the binding sequence of autolisins, proteins expressed by bacteriophages that specifically bind the wall of Mycobacteria species (the agent causing tuberculosis). I will thus create fusion antibodies (Ab) characterized by (i) the binding sequence of mycobacteriophages autolisins (for selective recognising intracellular Mycobacterial wall) and (ii) an effector region promoting bacterial clearance through either the macrophage-triggered phagocytosis or an ubiquitin-proteasome system. This therapy will represent a complete revolution in the field of new antimicrobial development, as it will combine complete bacterial eradication, development of memory immunity and fight against drug resistance, the three core pillars of this project. The super-selective polymersomes carrying the Abs-based universal therapy will be combined with the development of chimeric antigen receptor T-cells (CAR-T) against infection. These T-cells will be designed to chase and eradicate circulating infected cells in model organism.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores